Psyence Biomedical (PBM) corrects error in 2023 equity incentive plan
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Psyence Biomedical Ltd. filed a Form 6-K as a foreign private issuer to report a technical change to its 2023 Equity Incentive Plan. On May 4, 2026, the board approved an amendment and restatement of the plan to correct a typographical error in Section 4(b).
The updated plan, referred to as the First Amended and Restated Equity Incentive Plan, is provided in full as Exhibit 10.1. The filing does not describe any change to plan substance beyond this correction and is signed by the company’s Chief Financial Officer, Warwick Corden-Lloyd.
Positive
- None.
Negative
- None.
Key Terms
foreign private issuer, 2023 Equity Incentive Plan, amended and restated, First Amended and Restated Plan, +1 more
5 terms
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
2023 Equity Incentive Plan financial
"to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan"
amended and restated regulatory
"approved a resolution to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan"
First Amended and Restated Plan financial
"description of the amended and restated Plan (the “First Amended and Restated Plan”)"
Exhibit 10.1 regulatory
"furnished as Exhibit 10.1 hereto and incorporated herein by reference"
FAQ
What did Psyence Biomedical (PBM) change in its 2023 Equity Incentive Plan?
Psyence Biomedical corrected a typographical error in Section 4(b) of its 2023 Equity Incentive Plan. The board approved an amended and restated version, called the First Amended and Restated Equity Incentive Plan, which is provided in full as Exhibit 10.1 to the Form 6-K.
When did Psyence Biomedical (PBM) approve the amendment to its equity plan?
The board of Psyence Biomedical approved the amendment and restatement of its 2023 Equity Incentive Plan on May 4, 2026. This action is reported in a Form 6-K for June 2026 and formally documented through the First Amended and Restated Equity Incentive Plan.
Where can investors see the full text of Psyence Biomedical’s amended 2023 equity plan?
The complete First Amended and Restated Equity Incentive Plan is included as Exhibit 10.1 to the Form 6-K. The filing states that the brief description is qualified in its entirety by reference to this full exhibit, which contains the detailed plan terms.
Does Psyence Biomedical’s Form 6-K describe major changes to compensation or just a correction?
The Form 6-K explains that the 2023 Equity Incentive Plan was amended and restated to correct a typographical error in Section 4(b). It characterizes this as a corrective update, without describing broader or substantive changes to the plan’s overall structure or purpose.
What type of SEC filer is Psyence Biomedical (PBM) in this submission?
Psyence Biomedical submitted this report as a foreign private issuer on Form 6-K under Rules 13a-16 or 15d-16. The filing covers the month of June 2026 and reports the technical amendment to the company’s 2023 Equity Incentive Plan approved in May 2026.